Antiviral Mechanisms of Curcumin and Its Derivatives in Prevention and Treatment of COVID-19: A Review

Golpour-Hamedani, Sahar; Pourmasoumi, Makan; Askari, Gholamreza; Bagherniya, Mohammad; Majeed, Muhammed; Guest, Paul C.; Sahebkar, Amirhossein

doi:10.1007/978-3-031-28012-2_21

Cited by 4 publications

(2 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Curcumin can improve COVID-19 patients’ prognoses by drastically reducing the length of common symptoms, hospital stays, and mortality [ 95 ]. It inhibits the ACE2 receptor and the SARS-CoV-2 S protein, as well as SARS-CoV-2 proteases such as papain-like protease and main protease [ 96 , 97 ]. Additionally, curcumin can dramatically lower inflammatory cytokine levels and stimulate anti-inflammatory pathways, which raises anti-inflammatory cytokine levels and partially restores the pro- and anti-inflammatory chemical balance in COVID-19 patients.…”

Section: Mechanism Of Photodynamic Action Against Sars-cov-2mentioning

confidence: 99%

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review

Law,

Leung,

2023

Pharmaceuticals

View full text Add to dashboard Cite

Coronavirus disease 19 (COVID-19) has occurred for more than four years, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is a strain of coronavirus, which presents high rates of morbidity around the world. Up to the present date, there are no therapeutics that can avert this form of illness, and photodynamic therapy (PDT) may be an alternative approach against SARS-CoV-2. Curcumin and methylene blue have been approved and used in clinical practices as a photosensitizer in PDT for a long time with their anti-viral properties and for disinfection through photo-inactivated SARS-CoV-2. Previously, curcumin and methylene blue with antibacterial properties have been used against Gram-positive bacteria, Staphylococcus aureus (S. aureus), and Gram-negative bacteria, Escherichia coli (E. coli), Enterococcus faecalis (E. faecalis), and Pseudomonas aeruginosa (P. aeruginosa). Methods: To conduct a literature review, nine electronic databases were researched, such as WanFang Data, PubMed, Science Direct, Scopus, Web of Science, Springer Link, SciFinder, and China National Knowledge Infrastructure (CNKI), without any regard to language constraints. In vitro and in vivo studies were included that evaluated the effect of PDT mediated via curcumin or methylene blue to combat bacteria and SARS-CoV-2. All eligible studies were analyzed and summarized in this review. Results: Curcumin and methylene blue inhibited the replication of SARS-CoV-2. The reactive oxygen species (ROS) are generated during the treatment of PDT with curcumin and methylene blue to prevent the attachment of SARS-CoV-2 on the ACE2 receptor and damage to the nucleic acids either DNA or RNA. It also modulates pro-inflammatory cytokines and attenuates the clotting effects of the host response. Conclusion: The photodynamic action of curcumin and methylene blue provides a possible approach against bacteria and SARS-CoV-2 infection because they act as non-toxic photosensitizers in PDT with an antibacterial effect, anti-viral properties, and disinfection functions.

show abstract

Section: Mechanism Of Photodynamic Action Against Sars-cov-2mentioning

confidence: 99%

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review

Law,

Leung,

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic has highlighted the necessity of developing fast and effective control measures to avoid viral dispersion, disease severity, and health system collapse ( Martins et al., 2023 ; Thakkar et al., 2023 ). These control procedures included varied approaches, from social distancing to the development of antivirals and vaccines for a long-term protection strategy ( Golpour-Hamedani et al., 2023 ; Thakkar et al., 2023 ). In this scenario, many pharmacological interventions were proposed to improve immune coverage against SARS-CoV-2, resulting in different vaccines, with different mechanisms to induce immune response, being approved to the population ( Zhou et al., 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol

Campos,

Almeida,

Filgueiras

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionSARS-CoV-2 vaccines production and distribution enabled the return to normalcy worldwide, but it was not fast enough to avoid the emergence of variants capable of evading immune response induced by prior infections and vaccination. This study evaluated, against Omicron sublineages BA.1, BA.5 and BQ.1.1, the antibody response of a cohort vaccinated with a two doses CoronaVac protocol and followed by two heterologous booster doses.MethodsTo assess vaccination effectiveness, serum samples were collected from 160 individuals, in 3 different time points (9, 12 and 18 months after CoronaVac protocol). For each time point, individuals were divided into 3 subgroups, based on the number of additional doses received (No booster, 1 booster and 2 boosters), and a viral microneutralization assay was performed to evaluate neutralization titers and seroconvertion rate. ResultsThe findings presented here show that, despite the first booster, at 9m time point, improved neutralization level against omicron ancestor BA.1 (133.1 to 663.3), this trend was significantly lower for BQ.1.1 and BA.5 (132.4 to 199.1, 63.2 to 100.2, respectively). However, at 18m time point, the administration of a second booster dose considerably improved the antibody neutralization, and this was observed not only against BA.1 (2361.5), but also against subvariants BQ.1.1 (726.1) and BA.5 (659.1). Additionally, our data showed that, after first booster, seroconvertion rate for BA.5 decayed over time (93.3% at 12m to 68.4% at 18m), but after the second booster, seroconvertion was completely recovered (95% at 18m). DiscussionOur study reinforces the concerns about immunity evasion of the SARS-CoV-2 omicron subvariants, where BA.5 and BQ.1.1 were less neutralized by vaccine induced antibodies than BA.1. On the other hand, the administration of a second booster significantly enhanced antibody neutralization capacity against these subvariants. It is likely that, as new SARS-CoV-2 subvariants continue to emerge, additional immunizations will be needed over time.

show abstract

Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders

Ashique,

Mishra,

Mantry

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Antiviral Mechanisms of Curcumin and Its Derivatives in Prevention and Treatment of COVID-19: A Review

Cited by 4 publications

References 71 publications

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol

Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders

Contact Info

Product

Resources

About